BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 25345427)

  • 21. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
    Bogman K; Brumm J; Hofmann C; Giraudon M; Niggli M; Sturm-Pellanda C; Sauter A; Sturm S; Mangold B; Schmitt C
    Clin Pharmacokinet; 2019 Sep; 58(9):1205-1214. PubMed ID: 30968335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
    Martin P; Gillen M; Ritter J; Mathews D; Brealey C; Surry D; Oliver S; Holmes V; Severin P; Elsby R
    Drugs R D; 2016 Mar; 16(1):93-107. PubMed ID: 26748647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Murphy J; Curtin C; Mamidi RN; Weiner S; Wang SS; Ariyawansa J; Stieltjes H; Wajs E; Di Prospero NA; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):115-28. PubMed ID: 25407255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
    Kasserra C; Li J; March B; O'Mara E
    Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
    Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
    Jacobsen LV; Vouis J; Hindsberger C; Zdravkovic M
    J Clin Pharmacol; 2011 Dec; 51(12):1696-703. PubMed ID: 21228406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
    Chen J; Bhansali S; Neelakantham S; Trusley C; Majumdar T; Rebello S; Sunkara G; Meyers C
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):317-24. PubMed ID: 25740268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
    de la Peña A; Cui X; Geiser J; Loghin C
    Clin Pharmacokinet; 2017 Nov; 56(11):1415-1427. PubMed ID: 28357715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Sabo JP; Lang B; Elgadi M; Huang F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
    Bækdal TA; Borregaard J; Hansen CW; Thomsen M; Anderson TW
    Clin Pharmacokinet; 2019 Sep; 58(9):1193-1203. PubMed ID: 30945118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.